Patsy Reitman, president of the RX Border Defense Committee, shared concerns about the implications of health security in the U.S., suggesting that the country is a significant player in the global obesity epidemic. She described China’s potential influence in this area as a “test balloon.” Participating in this discussion were Senator Jim Banks from Indiana, Senator Tom Cotton from Arkansas, former Homeland Security Secretary Chad Wolf, former U.S. Trade Representative Jeff Gerrish, and RX Border Defense director Raul Lopez.
Reitman and Lopez, with Breitbart News Washington Bureau Chief Matthew Boyle, delved into the health security threats posed by China’s dominance in healthcare and the risks associated with America’s inadequate responses.
Reitman pointed out that China can saturate the U.S. market with products and raw materials without many consumers being aware of it. She recounted her experience of typing “obesity drug ads” into Google, which resulted in a flurry of targeted advertisements—29 in only about an hour. “Even though I’m fairly knowledgeable about this topic, I couldn’t find out where these drugs were made or their ingredients,” she remarked.
Her worries are centered around the quality of medicines crossing into the U.S. “The companies that are not stopped at the border are numerous; over half of them are from China. While the FDA maintains rigorous standards for U.S. citizens and companies, similar expectations aren’t always applied to imports,” she noted.
For instance, Reitman cited a Chinese company that had failed tests due to contamination from insects and bacteria yet remained on the “approved list” for certain obesity drugs. She flagged the complexity of the issues at hand and their serious risks.
She suggested that negative effects from these ingredients might not be reported as thoroughly as in traditional medical channels. “Price and convenience dominate online purchasing decisions, leading consumers to overlook potential long-term consequences,” she cautioned, lending an example of a woman from Kentucky who experienced kidney failure after a month of using weight-loss drugs.
Reitman also highlighted the adverse ramifications for American pharmaceutical industries that adhere to FDA regulations while China sidesteps those rules to expand its biotech sector. “We invest significantly in research and development of new treatments,” she said. “We’re considered leaders in this field, but if China continues to exert financial and systemic influence on our healthcare, it could undermine our efforts as Americans.”
She added, “This situation poses health risks for Americans and economic challenges in developing solutions for future health issues.”
Regarding the expenses entailed in drug development and the consequences for consumers, Reitman expressed her strong opposition to price regulation. “Capping prices might seem beneficial, but it leads to a detrimental effect on our system, introducing an element of socialization in drug pricing,” she argued.
Gerrish, also supportive of Reitman’s viewpoint, highlighted that such price controls could ultimately benefit China amid its ascent to global prominence. “This approach will reduce revenue for our pharmaceutical industry at a crucial time,” he warned.
Lopez chimed in on the issues of cost and the quality of raw materials, stating, “It’s clear we need to hold China to the same standards we expect from American companies. Our priority should be increased accountability and transparency, recognizing that China’s intentions may not align with the interests of the American people.”
